NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?

NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends Endocrinol Metab. 2019 Oct 17;: Authors: Stols-Gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG Abstract The prevalence of non-alcoholic fatty liver disease (NAFLD) is strongly increasing and may put patients at increased risk for atherosclerotic cardiovascular disease (asCVD). Both disease phenotypes often co-occur, in the case of obesity, insulin resistance, diabetes mellitus type 2, and the metabolic syndrome. We explore the pathogenesis of NAFLD, the epidemiology of asCVD in NAFLD patients, shared drivers of both phenotypes, and factors caused by NAFLD that contribute to asCVD. Genetic studies support that NAFLD may drive asCVD through mixed hyperlipidemia. Next, we discuss the prospects of lifestyle improvement and pharmacological treatment of NAFLD for asCVD risk reduction. Finally, we point out that earlier identification of patients with NAFLD should be pursued by increasing awareness of the association of these two phenotypes and collaboration between the involved physicians. PMID: 31630897 [PubMed - as supplied by publisher]
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Tags: Trends Endocrinol Metab Source Type: research